Company "Merck Sharp & Dohme" (MSD), which has been present on the local market since 1996, works on the obtaining of the approval for sale of revolutionary vaccine against uterine cancer named "Silgard" in Serbia.
Let us remind that the Advisory Board for Immunization of the American CEnter for Control and Prevention of Diseases unanimously backed the recommendation that the girls and women, aged between 11 and 26, should be vaccinated with the MSD vaccine, which is called "gardasil" in USA. Company "Merck" tested "gardasil" on 27,000 women in 33 countries and the results of the clinical testing showed that the vaccine was 100% efficient aggainst the viruses that are responsilbe for 70% of infections caused by human papilloma virus.
By the way, the uterine cancer is the second most often type of that women's disease. Every year, half million new cases are registered.